Scribd Logo
Upload

Welcome to Scribd!

  • APL Annual Report 2018 19 1 2

    Uploaded by

    Srinivas
    13 views2 pages
    The annual report summarizes Aurobindo Pharma's financial performance for 2018-19. It highlights key metrics like total revenue of Rs. 195,636 million, EBITDA of Rs. 39,519 million, and profit after tax of Rs. 23,647 million. The report also outlines Aurobindo Pharma's strategic priorities to lead with a range of products, expand into new areas, attain capabilities and strengthen compliance, and promote execution-oriented growth.

    Original Description:

    Original Title

    APL-Annual-Report-2018-19-1-2

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    The annual report summarizes Aurobindo Pharma's financial performance for 2018-19. It highlights key metrics like total revenue of Rs. 195,636 million, EBITDA of Rs. 39,519 million, and profit after tax of Rs. 23,647 million. The report also outlines Aurobindo Pharma's strategic priorities to lead with a range of products, expand into new areas, attain capabilities and strengthen compliance, and promote execution-oriented growth.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    13 views2 pages

    APL Annual Report 2018 19 1 2

    Uploaded by

    Srinivas
    The annual report summarizes Aurobindo Pharma's financial performance for 2018-19. It highlights key metrics like total revenue of Rs. 195,636 million, EBITDA of Rs. 39,519 million, and profit after tax of Rs. 23,647 million. The report also outlines Aurobindo Pharma's strategic priorities to lead with a range of products, expand into new areas, attain capabilities and strengthen compliance, and promote execution-oriented growth.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 2

    L

    LEAD WITH
    A RANGE OF
    PRODUCTS

    E
    EXPAND INTO
    NEW AREAS

    A
    ATTAINING
    CAPABILITIES AND
    STRENGTHENING
    COMPLIANCE

    P
    PROMOTE AN
    EXECUTION-ORIENTED
    GROWTH MINDSET

    ANNUAL REPORT 2018-19


    KEY FINANCIAL HIGHLIGHTS OF 2018-19

    TOTAL REVENUE EBITDA

    D195,636 MILLION
    D39,519 MILLION

    PAT EPS

    D23,647 MILLION
    D40.36

    CONTENTS
    COMPANY OVERVIEW STATUTORY REPORTS
    02 Introducing Aurobindo Pharma 36 Notice
    04 Worldwide Presence 48 Board's Report
    06 Business Overview 60 Management Discussion and Analysis
    08 Key Performance Indicators 68 Management of Risks
    10 Vice Chairman’s Review 78 Business Responsibility Report
    12 Managing Director’s Message 116 Report on Corporate Governance
    14 Business Model
    16 Lead with a Range of Products FINANCIAL STATEMENTS
    20 Expand into New Areas
    134 Standalone Financial Statements
    24 Attain Capabilities and Strengthening Compliance
    201 Consolidated Financial Statements
    28 Promote an Execution-oriented Growth Mindset
    30 Board of Directors
    32 Environment, Health and Safety
    34 Corporate Social Responsibility

    https://www.aurobindo.com/investors/results-
    reports-presentations/annual-reports/

    You might also like